TICKERNERD
Menu
ANIKANIKHealthcare · Drug Manufacturers - Specialty & Generic

ANIK Stock Forecast: Anika Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$21
+7.55% on the day

The 2 Wall Street analysts covering Anika Therapeutics, Inc. hold a median 12-month price target of $21 — +1.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$256.5M
Ticker Nerd rank
100 / 100
Median analyst target
$21
Analysts covering
2
Total return, dividends reinvested
1W
+38.0%
1M
+35.0%
YTD
+115.8%
1Y
+140.0%
From 52W high
0.0%
From 52W low
+155.7%
$8
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANIK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Anika Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
100 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
96
Growth
95
Value
90
Issuance
81
Momentum
81
Quality
73
Volatility
70
Size
64
Accruals
60

Revisions (96): Analysts have, on balance, been raising their forecasts.

Accruals (60): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

The rank is the raw material. Whether the rules would actually own Anika Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

ANIK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANIK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Oct 25Jan 26Apr 26Jul 26ANIKHigh $21Median $21Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $21Median $21High $21

The green dot is the last close — the median target sits +1.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 July 2026B. Riley SecuritiesMaintainsBuy$18 → $21
27 Feb 2026Barrington ResearchMaintainsOutperform$16 → $17
27 Feb 2026Barrington ResearchMaintainsOutperform—
9 Jan 2026Barrington ResearchMaintainsOutperform—
6 Nov 2025Barrington ResearchMaintainsOutperform—
23 Sept 2025Barrington ResearchMaintainsOutperform—
31 July 2025Barrington ResearchMaintainsOutperform—
12 May 2025Barrington ResearchMaintainsOutperform—
13 Mar 2025Barrington ResearchMaintainsOutperform—
1 Nov 2024Barrington ResearchMaintainsOutperform—
22 Oct 2024Barrington ResearchMaintainsOutperform—
9 Aug 2024Barrington ResearchMaintainsOutperform—
29 May 2024Stephens & Co.ReiteratesEqual-Weight—
9 May 2024Barrington ResearchMaintainsOutperform—
14 Mar 2024Barrington ResearchMaintainsOutperform—
14 Mar 2024Stephens & Co.ReiteratesEqual-Weight—
3 Jan 2024Barrington ResearchMaintainsOutperform—
3 Nov 2023Barrington ResearchMaintainsOutperform—
14 Aug 2023Barrington ResearchUpgradeOutperform—
10 Aug 2023Stephens & Co.MaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ANIK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+57.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

Anika Therapeutics, Inc. (ANIK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−25.4×

Cheaper than 97% of US stocks

Price / sales
2.1×

Cheaper than 51% of US stocks

Price / book
1.9×

Cheaper than 47% of US stocks

EV / EBITDA
80.5×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
15.6%

Higher than 66% of US stocks

Earnings growth (YoY)
15.6%

Higher than 57% of US stocks

Gross margin
65.1%

Higher than 79% of US stocks

Operating margin
11.4%

Higher than 69% of US stocks

Net margin
−3.1%

Higher than 26% of US stocks

Returns & dividend
Return on equity
−2.2%

Higher than 42% of US stocks

Return on assets
−0.9%

Higher than 40% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ANIK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ANIKAnika Therapeutics, Inc.$256.5M
100
TKNOAlpha Teknova, Inc.$268.1M
90
SIGASIGA Technologies, Inc.$234.3M
65
ORGOOrganogenesis Holdings, Inc.$300.8M
67
AKBAAkebia Therapeutics, Inc.$353.6M
76
EBSEmergent BioSolutions, Inc.$373.8M
95
EOLSEvolus, Inc.$380.0M
58
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANIK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ANIK news & analysis

Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript

Seeking Alpha · 29 July 2026neutral

Seeking Alpha published a transcript of Anika Therapeutics' Q2 2026 earnings call, summarizing management's discussion of the company's financial results and business performance for the quarter.

Why it matters — ANIK investors and analysts review earnings call transcripts for management commentary on operational trends, financial health, and strategic direction beyond what financial statements alone reveal.

Anika Therapeutics Q2 Earnings Call Highlights

MarketBeat · 29 July 2026positive

Anika Therapeutics reported higher second-quarter revenue, expanded gross margin, and its strongest adjusted EBITDA performance since 2020, driven by international commercial growth and manufacturing improvements.

Why it matters — The results signal that Anika's profitability is improving, which would be a key concern for investors monitoring the company's financial turnaround.

FAQ

Frequently asked questions about ANIK stock

What is the ANIK stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Anika Therapeutics, Inc. have a median 12-month price target of $21, with estimates ranging from $21 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANIK stock a buy right now?

Of the 2 analysts covering Anika Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anika Therapeutics, Inc. 100 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANIK?

As at 1 Aug 2026, Anika Therapeutics, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).

Will ANIK stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1.3% from the last close, and Ticker Nerd's factor model ranks Anika Therapeutics, Inc. 100 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANIK stock forecast for 2030?

No analyst covering Anika Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $21 over the next 12 months.

How has ANIK stock performed over the past year?

Anika Therapeutics, Inc. returned +140.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anika Therapeutics, Inc. do?

Anika Therapeutics Inc. is a joint preservation company specializing in the design, development, manufacturing, and commercialization of hyaluronic acid (HA)-based innovations for orthopedic care.

What is the latest news on ANIK?

The most recent item we track (Seeking Alpha, 29 July 2026): "Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Anika Therapeutics' Q2 2026 earnings call, summarizing management's discussion of the company's financial results and business performance for the quarter.

Company

About Anika Therapeutics, Inc.

Anika Therapeutics Inc. is a joint preservation company specializing in the design, development, manufacturing, and commercialization of hyaluronic acid (HA)-based innovations for orthopedic care. It focuses on early intervention solutions in osteoarthritis pain management, regenerative medicine, sports medicine, and bone-preserving joint solutions, delivered through products like Orthovisc, Monovisc, and Cingal for viscosupplementation injections that provide pain relief and restore joint function. The company also offers regenerative products such as Hyalofast and Tactoset for tissue repair, alongside non-orthopedic offerings including veterinary products like Hyvisc for equine joint issues, anti-adhesion barriers like Hyalobarrier for surgical use, and ophthalmic solutions. Anika Therapeutics Inc. partners with clinicians and distributes its portfolio globally to surgeons, hospitals, and ambulatory surgery centers, emphasizing minimally invasive treatments that delay invasive procedures and promote active living. Founded in 1992 and headquartered in Bedford, Massachusetts, it holds a leading position in HA-based osteoarthritis pain management in the U.S. market.

CEO Dr. Cheryl Renee Blanchard Ph.D. · 288 employees · United States · https://www.anika.com